Navigation Links
Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
Date:9/26/2007

cation in 2001 in the US, where it is marketed by Bayer HealthCare Pharmaceuticals Inc. as Campath(R), and in Europe, where it is named MabCampath(R).

Alemtuzumab is a humanized monoclonal antibody that binds to a specific target, CD52, on cell surfaces and directs the body's immune system to destroy those cells. It is the first and only monoclonal antibody approved by the FDA for the treatment of patients with B-CLL.

Genzyme and Bayer Schering Pharma AG, Germany are co-developing alemtuzumab in oncology, multiple sclerosis and other indications. Bayer Schering Pharma AG, Germany holds exclusive worldwide marketing and distribution rights to alemtuzumab.

Campath has a boxed warning which includes information on cytopenias, infusion reactions, and infections. The most commonly reported adverse reactions in patients with B-CLL were infusion reactions (fever, chills, hypotension, urticaria, nausea, rash, tachycardia, dyspnea), cytopenias (neutropenia, lymphopenia, thrombocytopenia, anemia), and infections (CMV viremia, CMV infection, other infections). In clinical trials, the frequency of infusion reactions was highest in the first week of treatment. Other commonly reported adverse reactions include vomiting, abdominal pain, insomnia and anxiety. The most commonly reported serious adverse reactions are cytopenias, infusion reactions, and immunosuppression/infections.

About Genzyme

One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 9,500 employees in locations spanning the globe and 2006 revenues of $3.2 billion. In 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation. In 2006 and 2007, Genzyme was selected by FORTUNE as one of the "10
'/>"/>

SOURCE Genzyme Corporation; Bayer Schering Pharma AG
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
2. Genzyme Announces Results of Clinical Trial of Hylastan
3. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
4. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
5. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
6. Genzyme Announces Successful Completion of Study Investigating Sevelamer Carbonate in Patients With Chronic Kidney Disease
7. Schering-Plough Announces Hepatitis C Data Presentations at Digestive Disease Week (DDW) 2007 Annual Meeting
8. Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
9. Schering-Plough Announces Presentation of Phase II Trial Results for Novel Oral Thrombin Receptor Antagonist at the 2007 Annual Meeting of The American College of Cardiology/i2 Summit
10. Sygnis Pharma AG announces date for presentation of clinical results
11. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... York , July 29, 2014 ... Transparency Market Research "Surgical Navigation Systems Market (Neurosurgical Navigation ... Global Industry Analysis, Size, Share, Growth, Trends and Forecast, ... was valued at USD 218.5 million in 2013 and ... from 2014 to 2020, to reach an estimated value ...
(Date:7/29/2014)... LAUDERDALE, Fla. , July 29, 2014 /PRNewswire-iReach/ ... medical service provider, has launched its Medical ... Program.  These services are tailored to the ... excellent standards prompted industry operators to propose that ... MHG Medical,s new program is intended to ...
(Date:7/29/2014)... BEDFORD, Mass. , July 29, 2014  Instrumentation Laboratory ... identity, including a new corporate logo. This is part of ... IL. Founded in Boston, MA ... Group family of companies since 1992.  Other companies in the ... ), Biokit and Systelab ( Barcelona, Spain ).  ...
Breaking Medicine Technology:Surgical Navigation Systems Market Expected to Reach USD 295.5 Million Globally in 2020: Transparency Market Research 2Surgical Navigation Systems Market Expected to Reach USD 295.5 Million Globally in 2020: Transparency Market Research 3Surgical Navigation Systems Market Expected to Reach USD 295.5 Million Globally in 2020: Transparency Market Research 4MHG Medical Management Services Aims to Change Cruise Industry Standard With New Equipment Maintenance Program 2Instrumentation Laboratory Unveils New Corporate Brand 2Instrumentation Laboratory Unveils New Corporate Brand 3
(Date:7/29/2014)... 2014 The Natural Multiple Sclerosis Treatment ... story to Gary M. Levin’s cure program. , ... for this serious disorder. Levin says that multiple sclerosis ... can be found in patients. , Dr. Gary ... many years, Levin has worked with patients suffering from ...
(Date:7/29/2014)... Winter is here down under, and ... Sydney’s central business district. That is, until a troop ... the otherwise ordinary day into a celebration—a celebration of ... advocates of The Truth About Drugs, a drug prevention ... They woke up the city with a rousing performance ...
(Date:7/29/2014)... Denver, Colorado (PRWEB) July 29, 2014 Daily ... is a 5 step holistic system that will permanently eliminate ... to Thomas Coleman his natural treatment will banish symptoms such ... ringing or beeping sound heard by patients will be gone ... 30 to 60 days. The author of this program says ...
(Date:7/29/2014)... July 29, 2014 (HealthDay News) --,The time at which ... their chances for survival, new research suggests. Showing ... or during holidays is associated with a 13 percent ... hours, researchers report. Every year, more than 250,000 ... severe type of heart attack, which is caused by ...
(Date:7/29/2014)... Although the bite of a brown recluse spider is ... an expert notes. It,s still important to recognize ... brown recluse spider bite, warned Dr. Donna Seger, medical ... potentially dangerous bites are on the rise. "As ... The [bite] has classic characteristics, but if physicians are ...
Breaking Medicine News(10 mins):Health News:Natural Multiple Sclerosis Treatment Review Reveals the Inside Story to Gary M. Levin’s Cure Program 2Health News:Sydney Business District “Rocked” by The Truth About Drugs 2Health News:Tinnitus Miracle Review Exposes the Only Holistic System for Tinnitus Cure 2Health News:Heart Attack Patients Treated at Night, Weekends May Have Worse Outcomes 2Health News:Brown Recluse Spider Bites on the Rise, Expert Warns 2
... HealthDay Reporter , THURSDAY, Oct. 27 (HealthDay News) ... speech therapy after suffering a massive stroke at the age ... a year-and-a-half completely isolated, unable to communicate, socialize or work ... in Texas, one of a handful of organizations cropping up ...
... , THURSDAY, Oct. 27 (HealthDay News) -- Nipple-sparing ... patients and women who have their breasts removed because ... a new study. For both groups of women, ... feeling reconstructed breast compared to other types of mastectomy, ...
... By Ellin Holohan HealthDay Reporter , ... a lifetime of problems after suffering head injuries from ... new study. From communication deficits to trouble with ... injuries can lead to "substantial long-term reduction" in quality ...
... Whitehead Institute scientists have determined that master transcription factors ... this way, signaling pathways are targeted to genes that ... gene expression to control cell state, growth, differentiation, and ... operate properly, a cell receives instructions from its neighbors ...
... of Nursing (NYUCN) received a two-year, $299,990.00 grant from ... (NCSBN) to research the "Impact of an Internationally Educated ... Nursing Homes." According to the Principal Investigator, Laura ... the NCSBN,s Patient Safety, Practice (LPN/VN, RN), and International ...
... By Maureen Salamon HealthDay Reporter , THURSDAY, Oct. 27 ... its frequent companion, drinking, may be as well, a new study ... week find a link between heavy boozing and a rise in ... hand, studies also suggest that heavier people are less likely to ...
Cached Medicine News:Health News:Speech Therapy Key to Stroke Rehab, But Many Miss Out 2Health News:Speech Therapy Key to Stroke Rehab, But Many Miss Out 3Health News:Nipple-Sparing Mastectomies May Be Right for Some 2Health News:Children With Head Injuries Can Face Lifetime of Problems 2Health News:Children With Head Injuries Can Face Lifetime of Problems 3Health News:How major signaling pathways are wired to our genome gives new insight into disease processes 2Health News:How major signaling pathways are wired to our genome gives new insight into disease processes 3Health News:Too Much Drinking May Raise Lung Cancer Risk: Study 2Health News:Too Much Drinking May Raise Lung Cancer Risk: Study 3
200 L, Racked, Pre-sterilized, 96 tips/rack, clear Recommended for 20, 25, 50, 100 and 200 L pipettes. Can also be used with 300 L pipettes when pipetting 200 L or less....
... Finntips have been designed to optimize the ... of our tip products is widely recognized ... range has been extended over the years ... standard and special tips including filter tips, ...
MBP's 200 L large orifice tip is perfect for handling fragile cells, viscous samples and genomic....
Designed to fit the Brinkmann Tranferpette and Treff Multi-Channel 300 L Pipettors, this tip provides extra space for repeat pipetting....
Medicine Products: